Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome
- PMID: 29161116
- DOI: 10.1164/rccm.201706-1172OC
Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome
Abstract
Rationale: Corticosteroid therapy is commonly used among critically ill patients with Middle East Respiratory Syndrome (MERS), but its impact on outcomes is uncertain. Analyses of observational studies often do not account for patients' clinical condition at the time of corticosteroid therapy initiation.
Objectives: To investigate the association of corticosteroid therapy on mortality and on MERS coronavirus RNA clearance in critically ill patients with MERS.
Methods: ICU patients with MERs were included from 14 Saudi Arabian centers between September 2012 and October 2015. We performed marginal structural modeling to account for baseline and time-varying confounders.
Measurements and main results: Of 309 patients, 151 received corticosteroids. Corticosteroids were initiated at a median of 3.0 days (quartile 1 [Q1]-Q3, 1.0-7.0) from ICU admission. Patients who received corticosteroids were more likely to receive invasive ventilation (141 of 151 [93.4%] vs. 121 of 158 [76.6%]; P < 0.0001) and had higher 90-day crude mortality (112 of 151 [74.2%] vs. 91 of 158 [57.6%]; P = 0.002). Using marginal structural modeling, corticosteroid therapy was not significantly associated with 90-day mortality (adjusted odds ratio, 0.75; 95% confidence interval, 0.52-1.07; P = 0.12) but was associated with delay in MERS coronavirus RNA clearance (adjusted hazard ratio, 0.35; 95% CI, 0.17-0.72; P = 0.005).
Conclusions: Corticosteroid therapy in patients with MERS was not associated with a difference in mortality after adjustment for time-varying confounders but was associated with delayed MERS coronavirus RNA clearance. These findings highlight the challenges and importance of adjusting for baseline and time-varying confounders when estimating clinical effects of treatments using observational studies.
Keywords: Saudi Arabia; coronavirus; corticosteroid; pneumonia; respiratory distress syndrome.
Comment in
-
Systemic Corticosteroid Therapy May Delay Viral Clearance in Patients with Middle East Respiratory Syndrome Coronavirus Infection.Am J Respir Crit Care Med. 2018 Mar 15;197(6):700-701. doi: 10.1164/rccm.201712-2371ED. Am J Respir Crit Care Med. 2018. PMID: 29227752 No abstract available.
Similar articles
-
Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study.Clin Infect Dis. 2020 Apr 15;70(9):1837-1844. doi: 10.1093/cid/ciz544. Clin Infect Dis. 2020. PMID: 31925415 Free PMC article.
-
Macrolides in critically ill patients with Middle East Respiratory Syndrome.Int J Infect Dis. 2019 Apr;81:184-190. doi: 10.1016/j.ijid.2019.01.041. Epub 2019 Jan 25. Int J Infect Dis. 2019. PMID: 30690213 Free PMC article.
-
Critically ill patients with diabetes and Middle East respiratory syndrome: a multi-center observational study.BMC Infect Dis. 2021 Jan 19;21(1):84. doi: 10.1186/s12879-021-05771-y. BMC Infect Dis. 2021. PMID: 33468070 Free PMC article.
-
Corticosteroid administration for viral pneumonia: COVID-19 and beyond.Clin Microbiol Infect. 2020 Sep;26(9):1171-1177. doi: 10.1016/j.cmi.2020.06.020. Epub 2020 Jun 27. Clin Microbiol Infect. 2020. PMID: 32603802 Free PMC article. Review.
-
[Infections with the MERS coronavirus--for the present no threat to Europe].Med Monatsschr Pharm. 2015 Dec;38(12):509-11. Med Monatsschr Pharm. 2015. PMID: 26837158 Review. German.
Cited by
-
Impact of corticosteroids on initiation and half-year durability of humoral response in COVID-19 survivors.Chin Med J Pulm Crit Care Med. 2024 Mar 15;2(1):48-55. doi: 10.1016/j.pccm.2024.02.005. eCollection 2024 Mar. Chin Med J Pulm Crit Care Med. 2024. PMID: 39170961 Free PMC article.
-
Recent advances in COVID-19-induced liver injury: causes, diagnosis, and management.Inflammopharmacology. 2024 Aug 10. doi: 10.1007/s10787-024-01535-7. Online ahead of print. Inflammopharmacology. 2024. PMID: 39126569 Review.
-
COVID-19: Recent Insight in Genomic Feature, Pathogenesis, Immunological Biomarkers, Treatment Options and Clinical Updates on SARS-CoV-2.Curr Genomics. 2024 Apr 8;25(2):69-87. doi: 10.2174/0113892029291098240129113500. Curr Genomics. 2024. PMID: 38751601 Review.
-
Repeated Pulses of Methyl-Prednisolone in Adults Hospitalized With COVID-19 Pneumonia and Acute Respiratory Distress Syndrome: A Preliminary Before-After Study (CortiCOVID Study).Open Respir Arch. 2021 Mar 19;3(2):100086. doi: 10.1016/j.opresp.2021.100086. eCollection 2021 Apr-Jun. Open Respir Arch. 2021. PMID: 38620829 Free PMC article.
-
[Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH)].Med Intensiva. 2021 Mar;45(2):104-121. doi: 10.1016/j.medin.2020.06.017. Epub 2020 Jul 11. Med Intensiva. 2021. PMID: 38620757 Free PMC article. Spanish.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical